Apnimed (NASDAQ:APMD) Sets New 12-Month Low – Should You Sell?

by · The Markets Daily

Apnimed, Inc. (NASDAQ:APMD – Get Free Report) shares hit a new 52-week low on Monday. The stock traded as low as $16.12 and last traded at $16.37, with a volume of 130,191 shares trading hands. The stock had previously closed at $16.40.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on APMD. Zacks Research upgraded shares of Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Wall Street Zen upgraded shares of Apnimed to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald started coverage on Apnimed in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock. Weiss Ratings initiated coverage on shares of Apnimed in a research note on Tuesday, October 27th. They issued a “sell (e-)” rating on the stock. Finally, Lifesci Capital started coverage on Apnimed in a report on Tuesday, August 25th. They issued an “outperform” rating and a $50.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $50.33.

Read Our Latest Report on Apnimed

Apnimed Price Performance

The stock has a market capitalization of $647.76 million and a PE ratio of 5.92. The business has a fifty day moving average price of $22.93.

Apnimed (NASDAQ:APMD – Get Free Report) last released its quarterly earnings data on Tuesday, September 8th. The company reported $0.51 EPS for the quarter. The company had revenue of $12.08 million during the quarter. On average, equities research analysts expect that Apnimed, Inc. will post -0.24 earnings per share for the current year.

Apnimed Company Profile

(Get Free Report)

Apnimed Inc is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA). The company is developing oral therapies intended to address the underlying physiological causes of OSA rather than relying solely on mechanical devices such as continuous positive airway pressure machines.

Apnimed’s lead program is AD109, an investigational once-daily oral therapy designed to improve upper-airway muscle activity during sleep.

Read More